Popular Articles

BioCis Pharma Starts A Phase I Clinical Trial With A New Cancer Drug
BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally.
drugs without prescription
Radiofrequency Ablation Is Effective Treatment For Barrett's Esophagus
A landmark clinical trial led by a University of North Carolina at Chapel Hill researcher concludes that radiofrequency ablation is an effective treatment for dysplasia in people with Barrett"s esophagus, a condition that can lead to deadly gastrointestinal cancer.
News of the day
Generation Of A Severe Memory-Deficit Mutant Mouse By Exclusively Eliminating The Kinase Activity Of CaMKIIalpha
Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) is an enzyme that adds phosphates to a variety of protein substrates to modify their functions. CaMKII alpha is enriched in the hippocampus, the memory center of the brain, and is believed to be an essential mediator of activity-dependent synaptic plasticity and memory functions. However, the causative role of the enzymatic activity of CaMKII alpha in such processes has not been demonstrated yet, because this enzyme has multiple protein functions other than the kinase activity. A Japanese research group, led by Dr Yoko Yamagata of the National Institute for Physiological Sciences, Japan, has successfully generated a novel kinase-dead mutant mouse of the CaMKII alpha gene that completely and exclusively lacks its kinase activity. They examined hippocampal synaptic plasticity and behavioral learning of the mouse, and found a severe deficit in both processes. They reported their findings in the Journal of Neuroscience, published on June 10, 2009.

Send email

Send email:
Your message:
Your name/organization:
Your E-mail:
Enter today\\'s date, 2 digits
(spam protection):